Match tier
Listed
Presence
Current · Arkansas
Last published
2019
Sources
OpenAlex · ORCID
Refreshed
2026-10-03
B
Research Areas
Biomedical Subjects
Biography and Research Information
Metrics
- h-index: 1
- Publications: 2
- Citations: 10
Selected Publications
-
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion (2019)PMC OpenAlex
-
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion (2019)
Collaboration Network
Top Collaborators
Landry K. Kamdem
Harding University Main Campus
2 shared publications
In database
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
Jingyue Xi
University of Michigan (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
Brandi L. Clark
Harding University Main Campus (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
Kelley M. Kidwell
University of Michigan (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
Ana-Maria Storniolo
Indiana University Health (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
Vered Stearns
Sidney Kimmel Comprehensive Cancer Center (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
Daniel F. Hayes
University of Michigan (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
Christina L. Gersch
University of Michigan (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
James M. Rae
University of Michigan (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
N. Lynn Henry
Huntsman Cancer Institute (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
Daniel L. Hertz
University of Michigan (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion